Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 54,988 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: MNKD-201(Nintedanib DPI), Placebo; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Fresno, California • Palm Springs, California • Doral, Florida + 5 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
Interventions: Pazopanib, Doxil; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 4
States / cities: Fort Myers, Florida • Orlando, Florida • Cincinnati, Ohio + 1 more

Conditions: Metabolic Syndrome
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 100 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neoplasm, Neoplasm Metastasis
Interventions: Abemaciclib, Clarithromycin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Memphis, Tennessee

Conditions: Low Back Pain
Interventions: Guideline Based Care plus Psychologically Informed Physical Therapy, Guideline Based Care (GBC); Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 2,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 5
States / cities: Baltimore, Maryland • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more

Conditions: Medication Adherence
Interventions: ID Capsule, Riboflavin, Prompts; Other · Dietary Supplement · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: SARS-CoV-2 Infection
Interventions: Coronavirus-specific T cell (CST); Biological
Lead sponsor: Children's National Research Institute; Other
Eligibility: 2 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Treatment Resistant Depression, Generalized Anxiety Disorder
Interventions: Genecept Assay; Device
Lead sponsor: Genomind, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 685 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chalfont, Pennsylvania

Conditions: Hypotension, Orthostatic
Interventions: Treatment Phase 1, Treatment Phase 2, Treatment Phase 3; Other · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Influenza, Respiratory Tract Infections
Interventions: Portal Reminders for Influenza Vaccination: Direct scheduling link, Portal Reminders for Influenza Vaccination: No direct scheduling link, Pre-Commitment Prompt, Pre-Appointment flu vaccine reminders; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 4 Months and older
Enrollment: 213,773 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Osteoarthritis
Interventions: Fixed Bearing or Mobile Bearing UKA; Device
Lead sponsor: Medacta USA; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Leesburg, Florida

Conditions: Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions: Berzosertib, Carboplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 14
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 11 more

Conditions: Adult Brain Glioblastoma
Interventions: Gadolinium, Ferumoxytol Non-Stoichiometric Magnetite, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Diffusion Weighted Imaging, MRI-Based Angiogram; Drug · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: PF-3512676 + Erlotinib, Erlotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 35
States / cities: Daphne, Alabama • Huntsville, Alabama • Mobile, Alabama + 30 more

Conditions: Juvenile Myelomonocytic Leukemia, Neurofibromatosis Type 1
Interventions: Bone Marrow Aspiration and Biopsy, Trametinib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Month to 21 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 57
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more

Conditions: Melanoma (Skin)
Interventions: BCG vaccine, autologous tumor cell vaccine, recombinant interferon alfa, chemotherapy, cyclophosphamide; Biological · Drug
Lead sponsor: AVAX Technologies; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 17
States / cities: Rancho Mirage, California • New Haven, Connecticut • North Miami Beach, Florida + 13 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: DWN12088, Placebo; Drug
Lead sponsor: Daewoong Pharmaceutical Co. LTD.; Industry
Eligibility: 40 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 20
States / cities: Mesa, Arizona • Phoenix, Arizona • San Francisco, California + 14 more

Conditions: Patients Implanted With Monofocal Intraocular Lens
Interventions: Monofocal Intraocular Lenses; Device
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Williamsburg, Virginia

Conditions: Advanced Solid Tumors - Phase 1 Population
Interventions: GPX-150 for Injection; Drug
Lead sponsor: Gem Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Chronic Granulomatous Disease
Interventions: Stem cell transplantation; Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: COPD Wellness, Health Advocate; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 95 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Head and Neck Cancer, Esophageal Cancer
Interventions: Not listed
Lead sponsor: University of Alberta; Other
Eligibility: 19 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Urinary Incontinence, Urinary Bladder, Overactive, Lower Urinary Tract Symptoms
Interventions: Preprocedure Telephone Call; Other
Lead sponsor: Boston Urogynecology Associates; Other
Eligibility: 18 Years and older · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Low Grade B-cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large-cell Lymphoma
Interventions: Clofarabine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Motivation-Audit-Positive Psychology Intervention Study

A Study of LY2835219 in Participants With Cancer

Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients

Smart Capsule for Automatic Adherence Monitoring

T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay

Orthostatic Hypotension in Rehabilitation Patients

Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- UCLA Portal R/R Influenza RCT 3

Fixed Bearing Versus Mobile Bearing Patient Satisfaction and Clinical Outcome Study

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy

Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

Prospective Evaluation of Near and Intermediate Visual Outcomes With Monofocal Intraocular Lenses: The Mast Study

Safety Study of GPX-150 in Patients With Solid Tumors

Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease

Rehabilitation for Patients With COPD

International Nutrition Audit in FORegut TuMors

Urodynamic Testing: Can we Improve Patient Experience?

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma